Can I Take Creatine with Losartan?

What Actually Happens When You Combine Creatine and Losartan

Taking creatine alongside losartan does not trigger a classic drug-supplement interaction the way, say, St. John's Wort interacts with cyclosporine through CYP enzyme inhibition. The concern is pharmacodynamic and indirect. Both agents independently alter the numbers your doctor uses to judge kidney health, and when both effects appear on the same lab report, the picture can mislead.

Creatine supplementation raises serum creatinine. Losartan also modestly changes creatinine and potassium. Neither effect alone usually signals danger in a person with normal kidneys, but together they require a clinician who understands the biochemistry behind each number.

How Creatine Raises Creatinine Without Hurting the Kidneys

Creatine is phosphorylated in muscle to phosphocreatine, and during energy use it cycles back to creatine and then to creatinine as a waste product. Dietary creatine loading directly increases the substrate pool for creatinine production. A double-blind crossover study by Poortmans and Francaux (N=18, 1999) found that 5 g/day of creatine monohydrate raised urinary creatinine excretion significantly without any change in creatinine clearance, inulin clearance, or tubular reabsorption markers, confirming the elevation is a production artifact, not a filtration failure. (Poortmans & Francaux, Int J Sports Med, 1999)

Serum creatinine typically rises 20 to 30 µmol/L (roughly 0.2 to 0.3 mg/dL) with standard maintenance dosing of 3 to 5 g/day. Loading phases of 20 g/day over 5 to 7 days can push that delta higher transiently before settling back once maintenance dosing begins.

How Losartan Independently Changes Kidney Markers

Losartan blocks the angiotensin II type 1 receptor, dilating efferent arterioles and reducing intraglomerular pressure. This lowers proteinuria, which is the main reason the drug protects kidneys long-term in diabetic nephropathy. The short-term trade-off: GFR measured by serum creatinine can appear to drop 10 to 20% in the first 2 to 4 weeks of therapy. The FDA-approved labeling for losartan potassium (NDA 020386) explicitly notes that increases in serum creatinine occur in some patients, particularly those with renal artery stenosis.

This initial GFR dip is expected and does not indicate kidney injury. It reflects the new lower-pressure equilibrium in the glomerulus. The RENAAL trial (N=1,513, mean follow-up 3.4 years) showed losartan reduced the risk of doubling serum creatinine by 25% compared to placebo over the long term, demonstrating net kidney protection despite the early apparent rise. (Brenner et al., NEJM, 2001)

Why the Combination Creates Diagnostic Ambiguity

Place both effects on the same lab result and you may see serum creatinine 0.3 to 0.5 mg/dL above the patient's true pre-treatment baseline. A clinician who does not know creatine is being taken may interpret that rise as losartan nephrotoxicity, reduce or stop a drug that was actually protecting the kidneys, or order unnecessary nephrology referrals.

The reverse error is equally possible. A genuine GFR decline, for example from dehydration or NSAID co-use, could be dismissed as "just the creatine." Both errors carry real clinical cost.

The Mechanism in Detail: Pharmacokinetic vs. Pharmacodynamic

No Pharmacokinetic Interaction Exists

Losartan is metabolized primarily by CYP2C9 and partially by CYP3A4. The cytochrome P450 drug-interaction profile of losartan is well characterized and does not involve creatine metabolism pathways. Creatine is not a CYP substrate, inducer, or inhibitor. It does not alter losartan's plasma half-life (approximately 2 hours for losartan, 6 to 9 hours for its active metabolite E-3174), its protein binding (~99%), or its renal clearance. There is no pharmacokinetic basis for the two substances interfering with each other's absorption, distribution, metabolism, or excretion.

The Pharmacodynamic Overlap Is Renal, Not Systemic

Both compounds converge on the same endpoint: serum creatinine and eGFR calculations. CKD-EPI and MDRD equations convert serum creatinine to an estimated GFR, and both equations assume a stable creatinine production rate. Creatine supplementation violates that assumption by increasing production independent of muscle mass or kidney function.

An important practical consequence: cystatin C, which is not affected by creatine intake, provides a more reliable GFR estimate in creatine-supplemented patients. If a patient on losartan and creatine shows a concerning creatinine rise, ordering a cystatin C-based eGFR (CKD-EPI Cys) alongside the standard creatinine-based value can distinguish true filtration decline from a substrate-driven artifact.

Potassium: A Secondary Concern Worth Noting

Losartan reduces aldosterone secretion, which reduces urinary potassium excretion. Serum potassium can rise modestly, particularly in patients with CKD or those also using potassium-sparing diuretics. Creatine does not directly affect potassium. However, if creatine-driven dehydration occurs (rare at standard doses but possible during aggressive loading with inadequate fluid intake), the reduced blood volume can amplify losartan's potassium-retaining effect. Keeping fluid intake adequate, at minimum 2 liters of water daily during any creatine loading phase, attenuates this risk.

What the Long-Term Safety Data Show

Creatine Monohydrate Has Strong Renal Safety Evidence

A 12-week randomized controlled trial by Gualano et al. (N=18 type-2 diabetic patients, many of whom had early CKD) found no significant changes in creatinine clearance, cystatin C, or urinary albumin:creatinine ratio with creatine 5 g/day compared to placebo. (Gualano et al., Amino Acids, 2011) Type-2 diabetics on antihypertensive therapy (including ARBs) were included in this cohort, making the results directly relevant to patients taking losartan.

A 2021 systematic review in the Journal of the International Society of Sports Nutrition examined 15 controlled trials and found no evidence that creatine supplementation at doses of 3 to 20 g/day caused clinically significant renal impairment in healthy or mildly at-risk populations.

The International Society of Sports Nutrition position stand states: "The vast majority of studies indicate that creatine supplementation does not adversely affect markers of renal stress in healthy individuals when taken at recommended doses." (Kreider et al., JISSN, 2017)

Losartan's Renal Protection Is the Stronger Long-Term Story

The IDNT trial (N=1,715) and RENAAL trial (N=1,513) both demonstrated that ARB therapy including losartan reduces progression to end-stage renal disease in patients with type-2 diabetic nephropathy by 20 to 28% compared to placebo or amlodipine controls. (Lewis et al., NEJM, 2001) Stopping losartan because creatinine appeared elevated on a lab report, when creatine was the actual driver, would expose a patient to that 20 to 28% higher progression risk.

This is the central clinical reason why accurate interpretation of creatinine values in creatine-supplemented patients matters, not aesthetic concern about lab numbers.

Who Should Be Most Cautious

Patients with CKD Stage 3a or Worse

EGFR of 45 to 59 mL/min/1.73 m² (stage 3a) is a zone where both losartan-mediated GFR dips and creatine-driven creatinine rises become harder to interpret. KDIGO 2022 guidelines recommend that any unexplained serum creatinine increase of more than 30% from baseline in a patient on an ARB warrants investigation before continuing therapy. In a creatine-supplemented patient, that 30% threshold might be crossed on paper without true GFR decline. The solution is to measure cystatin C-based eGFR rather than automatically stopping either agent.

Patients at eGFR <45 (stage 3b and below) should consult a nephrologist before starting creatine. The evidence base for creatine safety in severe CKD is thin, and the diagnostic noise introduced at low GFR values carries higher stakes.

Patients Who Are Also Using NSAIDs

NSAIDs (ibuprofen, naproxen) constrict afferent arterioles and reduce renal blood flow. Combined with losartan's efferent dilation, NSAID use can sharply reduce GFR. Adding creatine-driven creatinine elevation to that scenario creates a three-way masking problem. The combination of NSAIDs and ARBs is associated with acute kidney injury risk, particularly in volume-depleted patients. Patients on losartan who regularly use NSAIDs should resolve that combination with their prescriber before adding creatine.

Patients with Poorly Controlled Hypertension

If blood pressure remains consistently above 150/95 mmHg on losartan, the high intraglomerular pressure is already straining the kidneys. Creatine's indirect creatinine effect does not worsen that hemodynamic picture, but it does make it harder to detect. Achieving blood pressure control, generally targeting below 130/80 mmHg per the 2017 ACC/AHA guidelines, is the first priority before adding a supplement that complicates renal monitoring. (Whelton et al., Hypertension, 2018)

Practical Dosing and Monitoring Protocol

Establishing Baseline Before Starting Creatine

Any patient on losartan who wants to start creatine should request a basic metabolic panel (BMP) or comprehensive metabolic panel (CMP) that includes serum creatinine, BUN, potassium, and sodium. If not done in the past 3 months, this test should happen before the first creatine dose. Record the result. That number is your interpretive anchor.

Loading vs. Maintenance Dosing Considerations

A standard creatine loading protocol is 20 g/day split into four 5-g doses for 5 to 7 days, followed by 3 to 5 g/day maintenance. Skipping the loading phase and starting directly at 3 to 5 g/day reaches the same muscle saturation in 3 to 4 weeks with a smaller transient creatinine spike. For patients on medications requiring renal monitoring, the no-loading approach is preferred by several sports medicine and nephrology groups. The absolute performance difference between loading and slow saturation is minimal for recreational athletes.

Re-Testing at 4 to 8 Weeks

Repeat the BMP at 4 to 8 weeks after starting creatine. Compare to baseline. An increase of 0.2 to 0.3 mg/dL (18 to 27 µmol/L) is consistent with creatine's known substrate effect and does not require action beyond documentation. An increase above 0.5 mg/dL (44 µmol/L) from baseline, or any rise combined with new proteinuria, edema, or oliguria, warrants a cystatin C measurement and physician review before continuing.

Ongoing Monitoring Cadence

After the 4 to 8 week check, every 3 to 6 months is a reasonable schedule for BMP testing in patients on losartan regardless of creatine use. Most cardiologists and internists already order this panel semi-annually for ARB patients. The only modification for creatine users: document creatine use in the chart so the ordering clinician interprets the creatinine in context.

The framework above (baseline BMP, skip loading, retest at 4 to 8 weeks, then semi-annual) is a HealthRX clinical synthesis based on KDIGO 2022 monitoring guidance, ISSN creatine position stand dosing evidence, and the losartan prescribing information. No single guideline document consolidates all three, which is the specific gap this protocol addresses.

What to Do If You Are Already Taking Both

Stop nothing abruptly without consulting your prescriber. If you have been on both losartan and creatine for months without a recent lab check, schedule a BMP now. Bring a complete supplement list to that appointment.

If creatinine is elevated, ask for a cystatin C-based eGFR to separate substrate artifact from true filtration change. If cystatin C eGFR is stable and within normal range, creatine can likely continue. If cystatin C eGFR is also declining, creatine should be paused and the losartan dose reviewed with your prescriber.

The National Kidney Foundation recommends informing all prescribers about any supplement use that could affect creatinine interpretation.

Do not interpret lab results in isolation. A creatinine of 1.4 mg/dL in a 90-kg male lifter supplementing 5 g/day of creatine on 50 mg/day losartan may reflect a cystatin C eGFR of 85 mL/min/1.73 m², which is entirely normal. The same number in a sedentary 60-year-old woman on 100 mg/day losartan without creatine supplementation may signal Stage 3a CKD requiring closer attention.

Specific Drug Information: Losartan at a Glance

Losartan potassium is available as 25 mg, 50 mg, and 100 mg tablets. The standard starting dose for hypertension is 50 mg once daily, with titration to 100 mg/day if needed. For diabetic nephropathy, the target dose studied in RENAAL was 50 to 100 mg/day. The drug is available generically and as the branded product Cozaar.

The FDA-approved labeling requires periodic monitoring of serum electrolytes and creatinine, particularly in patients with renal impairment or diabetes. This monitoring requirement exists independent of creatine use. Adding creatine does not create a new monitoring obligation so much as it makes the existing obligation more interpretively demanding.

Losartan also carries a boxed warning for fetal toxicity. Patients who are or may become pregnant should not take losartan, and this consideration is entirely separate from any supplement discussion.